Modified Form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Application Number	10/749,121
Filing Date	December 30, 2003
First Named Inventor	Saunders et al.
Group Art Unit	~~1644~~ 1626
Examiner Name	~~Not Yet Assigned~~ BARKER
Attorney Docket Number	VPI/02-05 US

U.S. PATENT DOCUMENTS

Exam Initials	Cite No.	U.S. Patent Document No.	Publication Date	Name of Patentee(s) or Applicant(s)	Class	Sub Class	Filing Date If Appropriate
MB	A1	5,541,168	7/30/96	Sterling Winthrop Inc.	514	92	10/2/94
MB	A2	5,750,546	5/12/98	Sanofi Winthrop Inc.	514	342	12/2/94
MB	A3	5,512,576	4/30/96	Sterling Winthrop Inc.	514	258	12/2/94
MB	A4	5,494,925	2/27/96	Sterling Winthrop Inc.	514	362	12/2/94
MB	A5	5,550,139	8/27/96	The Wichita State University	514	362	8/27/96
MB	A6	~~5,556,09 2~~ 5,556,209	9/17/96	Sanofi Winthrop Inc.	514	362	12/2/94

FOREIGN PATENT DOCUMENTS

Exam Initials	Cite No.	Foreign Patent Document Office	Number	Name of Patentee(s) or Applicant(s)	Date of Publication	Translation Yes	No
MB	B1	EP	WO 03/082841 A1	Novartis AG	9 October 2003		

OTHER NON-PATENT LITERATURE DOCUMENTS

Exam Initials	Cite No.	Name of Author, Title (when appropriate), Publication, Volume, Page(s), Date, Etc.
MB	C1	Mantegani et al., "Synthesis And Antihypertensive Activity Of 2,4-Dioxoimidazolidin-1-yl And Perhydro-2,4-Dioxopyrimidin-1-yl Ergoline Derivatives", IL Farmaco, 53 (4): 293-304 (1998)
MB	C2	Bright et al, "Competitive Particle Concentration Fluorescence Immunoassays For Measuring Anti-Diabetic Drug Levels In Mouse Plasma", Journal of Immunological Methods, 207 (1): 23-31 (1997)
MB	C3	Albericio et al., "Synthesis of a Sulfahydantoin Library", J. Comb. Chem. 3, 290-300 (2001)
MB	C4	Kuang et al., "A General Inhibitor Scaffold for Serine Proteases with a (Chymo)trypsin-Like Fold: Solution-Phase Construction and Evaluation of the First Series of Libraries of Mechanism-Based Inhibitors", J. Am. Chem. Soc. 121 (35): 8128-8129 (1999)
MB	C5	Groutas et al, "Potent and Specific Inhibition of Human Leukocyte Elastase, Cathepsin G and Proteinase 3 by Sulfone Derivatives Employing the 1,2,5-Thiadiazolidin-3-one 1,1 Dioxide Scaffold, Bioorganic & Medicinal Chemistry 6 (6): 661-671 (1998)
MB	C6	Groutas et al, "Structure-Based Design of a General Class of Mechanism-Based Inhibitors of the Serine Proteinases Employing a Novel Amino Acid-Derived Heterocyclic Scaffold" Biochemistry, 36(16): 4739-4750 (1997)
MB	C7	Dewynter et al, "Synthesis of Pseudonucleosides Containing Chiral Sulfahydantoins as Aglycone (II)", Tetrahedron , 52 (3): 993-1004 (1996)
MB	C8	Muller et al., "A General Synthesis of 4-Substituted 1, 1-Dioxo-1,2,5-thiadiazolidin-3-ones Derived from alpha Amino Acids", J. Org. Chem., 54 (18): 4471-4473 (1989)
MB	C9	Lee et al, "3-Oxo and 3-Imino-4-substituted-1,2,5-thiadiazolidine 1,1-Dioxides: Synthesis, Spectral Properties, and Selected Chemistry", J. Org. Chem., 54 (13): 3077-3083 (1989)
MB	C10	Tremblay et al, "Efficient Solid-Phase Synthesis of Sulfahydantoins", J. Comb. Chem., 4 (5): 429-435 (2002)
MB	C11	Albericio et al, "Solid Phase synthesis of Sulfahydantoins", Tetrahedron Letters, 41 (17) 3161-3163 (2000)

* a copy of this reference is not provided as it was previously cited by or submitted to the office in a prior application, U.S.S.N. _____, filed _____, and relied upon for an earlier filing date under 35 U.S.C. §120 (continuation, continuation-in-part, and divisional applications).

Examiner	M. P. Bh	Date Considered	1·31·06

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered.

Include copy of this form with next communication to applicant.